Ultravist and Type i hypersensitivity - a phase IV clinical study of FDA data

Summary:

Type i hypersensitivity is reported as a side effect among people who take Ultravist (iopromide), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Candesartan Cilexetil, and have Computerised tomogram abdomen.

The phase IV clinical study analyzes which people have Type i hypersensitivity when taking Ultravist. It is created by eHealthMe based on reports of 9,241 people who have side effects when taking Ultravist from the FDA, and is updated regularly.

What is Ultravist?

Ultravist has active ingredients of iopromide. eHealthMe is studying from 9,246 Ultravist users. Check the latest studies of Ultravist.

What is Type i hypersensitivity?

Type i hypersensitivity is found to be associated with 134 drugs and 308 conditions by eHealthMe. Check the latest studies of Type i hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

9,241 people reported to have side effects when taking Ultravist.
Among them, 15 people (0.16%) have Type i hypersensitivity.

Could Ultravist cause Type i hypersensitivity?

Among these 15 people:

How long have people been on Ultravist when they have Type i hypersensitivity? *

What is the gender of people who have Type i hypersensitivity when taking Ultravist? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Type i hypersensitivity when taking Ultravist? *

What are other drugs people take besides Ultravist? *

Plavix: 5 people, 33.33%
Candesartan Cilexetil: 5 people, 33.33%
Symbicort: 1 person, 6.67%
Spiriva: 1 person, 6.67%
Seroquel: 1 person, 6.67%

What are other side effects people have besides Type i hypersensitivity? *

Swelling Face: 6 people, 40.00%
Rashes (redness): 6 people, 40.00%
Ventricular Fibrillation (abnormally irregular heart rhythm): 5 people, 33.33%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 5 people, 33.33%
Dyspnea (difficult or laboured breathing): 5 people, 33.33%
Gait Disturbance: 5 people, 33.33%
Anaphylactoid Shock (serious allergic reaction that is rapid in onset and may cause death): 5 people, 33.33%
Itching: 3 people, 20.00%
Nausea (feeling of having an urge to vomit): 2 people, 13.33%
Hypotension (abnormally low blood pressure): 2 people, 13.33%

What are the existing conditions these people have? *

Tonsil Cancer: 1 person, 6.67%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 6.67%
Computerised Tomogram Abdomen: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ultravist and have Type i hypersensitivity?

- Check whether Type i hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ultravist:

Ultravist (9,246 reports)

Browse all side effects of Ultravist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type i hypersensitivity:

Type i hypersensitivity (134 drugs)

Browse all the conditions that are associated with Type i hypersensitivity:

Type i hypersensitivity (308 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on iopromide (the active ingredients of Ultravist) and Ultravist (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.